ArticlePulmonary circulation2026
Shared Decision-Making During Pulmonary Arterial Hypertension Therapy Selection: A Patient and Clinician Survey.
Article in Pulmonary circulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selection of therapy for pulmonary arterial hypertension (PAH) requires tradeoffs among disease severity, therapeutic benefit, adverse effects, treatment burden, quality of life, and patient values. Although professional societies endorse shared decision-making (SDM) in this context, empirical data describing SDM in PAH are limited. We conducted a survey to characterize SDM during PAH treatment selection from both patient and clinician perspectives. Using the Ottawa Decision-Making Framework, we administered parallel surveys to patients and clinicians at the Pulmonary Hypertension Association's 2022 International PH Conference (Atlanta, GA). Survey items assessed decisional characteristics including role preference, confidence, self-efficacy, decisional support and the factors considered most important during PAH therapy selection. Surveys were administered electronically and analyses were performed using Python. A total of 89 participants (51 patients, 38 clinicians) completed the survey. Preference for SDM was nearly universal among patients (96%) and clinicians (95%). However, priorities differed significantly. Patients more frequently emphasized quality of life (81% vs. 54%) and efficacy of therapy (42% vs. 29%), whereas clinicians prioritized risk of disease progression (67% vs. 30%; all
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.